KDR and non-small cell lung carcinoma: In the present study, 9.5% of patients failed the trial screen because of low TMB, and subgroup analysis revealed comparable antitumor activity of camrelizumab plus apatinib in high-TMB patients with positive and negative PD-L1 expression, suggesting more efforts are needed to implement TMB or the other potent biomarkers to guide the combination of immunotherapy and VEGFR-TKIs in patients with NSCLC.